Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04145297 · ClinicalTrials.gov registry record · Phase 1
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04145297 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 16 participants.
The verdict
NCT04145297, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.
Interventions
- DRUG Ulixertinib
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2022-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04145297
The ClinicalTrials.gov registry entry for NCT04145297 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ulixertinib is the first listed.
NCT04145297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04145297 about?
NCT04145297 is a clinical study titled "Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas". Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.
What is the current status of trial NCT04145297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-03-17. Estimated completion is 2022-08-18.
What interventions are being tested in trial NCT04145297?
The interventions under investigation include: Ulixertinib (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04145297?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.